AbCellera Biologics Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbCellera Biologics Inc. (ABCL)
CIK: 0001703057
Period of Report: 2021-06-22

Reporting Person: Hayden Michael R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-22	Common Shares	S	100000	$25.50	Disposed	1003397	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	118245	Indirect

Footnotes

F1: On June 22, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.

F2: These shares are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein.